Biocon Ltd, in the pharma sector, witnessed a 40% decline from the December 2020 high but shows signs of a bullish trend. Traders are recommended to consider buying for target levels of 325-350. The daily Relative Strength Index (RSI) is at 65.0. RSI below 30 is oversold and above 70 is considered overbought, Trendlyne data showed.
As per Trendlyne data, the average target price of the stock is Rs 2,841, which shows a downside of 17% from the current market prices. The consensus recommendation from 12 analysts for the stock is a Buy .